Logotype for Tata Chemicals Limited

Tata Chemicals (TATACHEM) Q1 24/25 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Tata Chemicals Limited

Q1 24/25 earnings summary

2 Feb, 2026

Executive summary

  • Consolidated revenue for Q1 FY25 was ₹3,789 crore, up 9% sequentially but down from ₹4,218 crore year-over-year, with stable demand in India and robust trends in detergents, flat container glass, and solar glass.

  • EBITDA rose 30% sequentially to ₹574 crore, though down from ₹1,043 crore in Q1 FY24; PAT from continuing operations was ₹175 crore, up 21% sequentially but lower than ₹578 crore year-over-year.

  • Net debt increased to ₹4,789 crore from ₹4,163 crore in the previous quarter, mainly due to higher working capital loans and lease capitalization.

  • Operations focused on cost competitiveness, timely CapEx execution, and margin improvements in India and the U.S.

  • European soda ash market faced unfavorable conditions, impacting UK operations and leading to prior asset write-downs.

Financial highlights

  • India saw a meaningful decline in costs quarter-over-quarter, leading to margin expansion, while U.S. operations benefited from improved cost control and steady production.

  • U.K. margins declined due to lower volumes, reduced energy business earnings, and a one-off fine; Kenya margins were affected by higher shipping and transportation costs.

  • EBITDA margin improved to 15% in Q1 FY25 from 13% in Q4 FY24, but down from 25% in Q1 FY24; PAT margin at 5% in Q1 FY25, up from 4% sequentially, but down from 14% year-over-year.

  • Working capital debt increased by INR 800 crore, with an additional INR 170 crore from warehouse capitalization.

  • Gross debt rose to ₹6,376 crore from ₹5,563 crore in the previous quarter.

Outlook and guidance

  • Market conditions are expected to remain balanced through December, with stable or better volumes anticipated in all geographies except the U.K.

  • Capacity expansions in soda ash, sodium bicarbonate, and pharmaceutical salt are expected to add at least INR 400 crore to EBITDA on a full-year basis.

  • U.K. margins are expected to remain at current levels, with ongoing efforts to reduce losses through cost rationalization and portfolio adjustments.

  • Management highlighted ongoing challenges in European soda ash markets, with a persistently low pricing outlook impacting future cash flows.

  • Full utilization of new sodium bicarbonate capacity in India is targeted by the end of the financial year or early next year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more